Geisinger Taps EarlySign™ for New Range of AI Solutions to Identify Patients at Risk of High-Burden Diseases

Share:

Share on twitter
Share on linkedin
Share on facebook
Share on email

Geisinger Taps EarlySign™ for New Range of AI Solutions to Identify Patients at Risk of High-Burden Diseases

Multi-Year Partnership to Apply Lower GI Algorithms as First Step in Improving Patient Outcomes Through Personalized and Population Health Strategies

DANVILLE, PA and TEL AVIV, Israel – July 10, 2019Medial EarlySign (earlysign.com), a leader in machine learning-based solutions to aid in early detection and prevention of high-burden diseases, today announced it is partnering with Geisinger and its Steele Institute for Health Innovation to develop and deploy a suite of machine learning-based solutions to identify individuals at risk of a range of chronic and high-burden diseases.

Partnering with Geisinger’s Steele Institute for Health Innovation, EarlySign’s LGI-Flag™ solution will be deployed to help healthcare practitioners identify patients who are at risk for significant lower GI disorders.  LGI-Flag is an advanced software solution that analyzes medical data –including changes in routine blood tests – to flag individuals who will benefit from further evaluation. Reflecting the Steele Institute’s efforts to transform healthcare delivery by implementing solutions that improve health, patient experience, care delivery and affordability, the partnership will also explore additional opportunities to benefit patients and their care providers.

LGI-Flag has been used in healthcare systems around the world since 2015 to identify patients at risk for lower GI disorders associated with chronic occult bleeding. The technology will form the basis for Geisinger and EarlySign to address similar opportunities with other acute and chronic diseases. The partnership will benefit from Geisinger’s innovation infrastructure, unique data assets and world-class care teams.

“EarlySign’s technology and the LGI-Flag solution will potentially assist our teams to more quickly identify significant lower GI disorders and intervene earlier than we historically have been able to,” said Keith A. Boell, D.O., Associate Chief Quality Officer at Geisinger. “We look forward to advancing our use of this technology while leveraging our experience to help more patients benefit from these life-changing medical advances.”

“We are delighted to be partnering with Geisinger, which shares our commitment to innovation and to offering the most effective care for challenging health issues,” said Ori Geva, Co-founder and CEO of Medial EarlySign. “This is the first step of our ultimate goal: enabling healthcare systems to identify and connect with those high-risk patients and engage with them early enough via interventions that may prevent or delay disease progression.”

 

# # #

 

Share:

Share on twitter
Share on linkedin
Share on facebook
Share on email

Are you looking to solve high-burden disease challenges?